<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_WLC-Milwaukee_Parts skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:WLC-Milwaukee/Parts</SPAN></H1><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV id="wlcHeader" class="navLinks" style="z-index:5;top:14px;left:0px;position:fixed;height:90px;width:100%;"><TABLE width="100%" align="center" cellspacing="0"><TBODY><TR height="90px"><TD id="HomeBox"><A id="homeLink" href="https://2015.igem.org/Team:WLC-Milwaukee" style="text-decoration:none">Home</A></TD><TD id="ProjectBox"><A id="projectLink" href="https://2015.igem.org/Team:WLC-Milwaukee/Project" style="text-decoration:none">Project</A></TD><TD id="PartsBox"><A id="partsLink" href="https://2015.igem.org/Team:WLC-Milwaukee/Parts" style="text-decoration:none">Parts</A></TD><TD id="NotebookBox"><A id="notebookLink" href="https://2015.igem.org/Team:WLC-Milwaukee/Notebook" style="text-decoration:none">Documentation</A></TD><TD id="ModelingBox"><A id="modelingLink" href="https://2015.igem.org/Team:WLC-Milwaukee/Modeling" style="text-decoration:none">Modeling</A></TD><TD id="practBox"><A id="practLink" href="https://2015.igem.org/Team:WLC-Milwaukee/Practices">Policy</A></TD><TD id="teamBox"><A id="teamLink" href="https://2015.igem.org/Team:WLC-Milwaukee/Attributions">People</A></TD></TR></TBODY></TABLE></DIV><DIV id="container"><DIV id="element"><P>Parts</P></DIV></DIV><DIV style="padding-left:10%;padding-right:10%;font-size:11pt"><P>Of all the TolC proteins we used in our project, three were ultimately submitted to the BioBrick registry. These submitted parts were <I>tolC</I> homologs from <I>Yersenia pestis Angola</I> (BBa_K1683000), <I>Proteus mirabilis</I> (BBa_K1683002), and <I>Pseudomonas aeruginosa</I> PA01 (oprM) (BBa_K168004). These proteins were submitted as a part of larger constructs which we used to express usable <I>tolC</I> molecules in our chassis organism, <I>ΔtolC E. coli.</I> These constructs consist of 4 major components. First is the pBAD promoter, an arabinose-induced strong <I>E. coli</I> promoter. Second is the strong <I>E. coli</I> ribosomal binding site (originally from BBa_B0034). Third is the <I>E. coli tolC</I> signaling sequence; this forms a chimeric protein with the <I>tolC</I> or <I>tolC</I> homolog of interest. See Project &gt; Solution &gt; TolC for more information on TolC.</P><P>These parts were characterized by western blotting and through Kirby-Bauer antibiotic assays. All three western blots showed increased protein expression with the inducer present. <I>Yersenia pestis</I> and <I>Proteus mirabilis</I> TolC proteins were even able efflux Novobiocin and Erythromycin as evidenced by the Kirby-Bauer assays. More detailed analysis is found on the Documentation page’s Results section.  </P></DIV><H4>Part Table </H4>&lt;groupparts&gt;iGEM015 WLC-Milwaukee&lt;/groupparts&gt;</DIV></DIV></DIV></DIV></BODY></HTML>